Elekta's Leksell Gamma
Knife Icon
Knife Icon
Elekta and Australia's GenesisCare enter $100 million partnership
March 31, 2016
by Christina Hwang, Contributing Reporter
As part of an eight year contract that is valued at more than $100 million, Elekta has formed a partnership with GenesisCare, Australia's largest radiotherapy provider.
The deal will include the acquisition of certain Elekta modalities, such as Leksell Gamma Knife Icon radiosurgery systems and Versa HD linear accelerators, brachytherapy systems, software and equipment services.
Leksell Gamma Knife limits radiation dose to healthy tissue and is the only technology with microradiosurgery capabilities, allowing for the treatment of almost any target in the brain with ultrahigh accuracy, says Elekta.
Versa HD allows for custom configuration for clinical needs, and provides delivery of stereotactic radiotherapy and stereotactic radiosurgery in a standard time slot.
Although not expected to be available in the market until 2017, Elekta’s MR-guided linear accelerator will also be acquired by GenesisCare as part of the arrangement.
“The MR-linac is a game changer. We expect cancer patients, including those receiving treatment for prostate, breast and other cancers, to benefit from this innovation.” said Dan Collins, GenesisCare managing director, in a statement.
Software systems included in the agreement are MOSAIQ enterprise licensing, which provides an oncology information system (OIS) to enable an automated workflow across their entire global enterprise. The deal also includes METRIQ, a fully integrated cancer registry for data collection and follow-up through reporting and analysis.
The goal of GenesisCare is to transform health care and improve outcomes for cancer patients on a global scale, according to the announcement, and an important factor is the harmonization of its practices and cancer management technology available for its medical teams.
“We are proud to partner alongside GenesisCare and support their exciting vision,” said Tomas Puusepp, president and CEO of Elekta, in a statement.
These products and solutions will be available in GenesisCare cancer treatments in Australia, the U.K. and new markets.
Elekta has also formed alliances with McLaren Health Care and Spire Healthcare in 2013, and the Centre hospitalier de l'Université de Montréal and Avera Health in 2014.
The deal will include the acquisition of certain Elekta modalities, such as Leksell Gamma Knife Icon radiosurgery systems and Versa HD linear accelerators, brachytherapy systems, software and equipment services.
Leksell Gamma Knife limits radiation dose to healthy tissue and is the only technology with microradiosurgery capabilities, allowing for the treatment of almost any target in the brain with ultrahigh accuracy, says Elekta.
Versa HD allows for custom configuration for clinical needs, and provides delivery of stereotactic radiotherapy and stereotactic radiosurgery in a standard time slot.
Although not expected to be available in the market until 2017, Elekta’s MR-guided linear accelerator will also be acquired by GenesisCare as part of the arrangement.
“The MR-linac is a game changer. We expect cancer patients, including those receiving treatment for prostate, breast and other cancers, to benefit from this innovation.” said Dan Collins, GenesisCare managing director, in a statement.
Software systems included in the agreement are MOSAIQ enterprise licensing, which provides an oncology information system (OIS) to enable an automated workflow across their entire global enterprise. The deal also includes METRIQ, a fully integrated cancer registry for data collection and follow-up through reporting and analysis.
The goal of GenesisCare is to transform health care and improve outcomes for cancer patients on a global scale, according to the announcement, and an important factor is the harmonization of its practices and cancer management technology available for its medical teams.
“We are proud to partner alongside GenesisCare and support their exciting vision,” said Tomas Puusepp, president and CEO of Elekta, in a statement.
These products and solutions will be available in GenesisCare cancer treatments in Australia, the U.K. and new markets.
Elekta has also formed alliances with McLaren Health Care and Spire Healthcare in 2013, and the Centre hospitalier de l'Université de Montréal and Avera Health in 2014.